These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32035695)

  • 1. Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma.
    Inoue H; Yokota T; Hamauchi S; Onozawa Y; Kawakami T; Shirasu H; Notsu A; Yasui H; Onitsuka T
    Auris Nasus Larynx; 2020 Aug; 47(4):650-657. PubMed ID: 32035695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
    Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
    Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
    Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
    Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.
    Tsujikawa T; Ohno K; Morita KI; Saburi S; Mitsuda J; Yoshimura K; Kimura A; Morimoto H; Ogi H; Shibata S; Akashi T; Kurata M; Imoto I; Shimizu Y; Kano S; Watanabe A; Yamazaki T; Asada Y; Hayashi R; Saito Y; Ozawa H; Tsukahara K; Oridate N; Sano D; Horii A; Ueki Y; Maruo T; Mukoyama N; Hanai N; Fukusumi T; Iwai H; Fujisawa T; Fujii T; Nibu KI; Iwae S; Ueda T; Chikuie N; Yasumatsu R; Matsuo M; Umeno H; Ono T; Masuda M; Toh S; Itoh K; Hirano S; Asakage T
    Front Immunol; 2024; 15():1390873. PubMed ID: 39136017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
    Saba NF; Wong SJ; Nasti T; McCook-Veal AA; McDonald MW; Stokes WA; Anderson AM; Ekpenyong A; Rupji M; Abousaud M; Rudra S; Bates JE; Remick JS; Joshi NP; Woody NM; Awan M; Geiger JL; Shreenivas A; Samsa J; Ward MC; Schmitt NC; Patel MR; Higgins KA; Teng Y; Steuer CE; Shin DM; Liu Y; Ahmed R; Koyfman SA
    JAMA Oncol; 2024 Jul; 10(7):896-904. PubMed ID: 38780927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
    Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.
    Ito T; Okamoto I; Tokashiki K; Sato H; Okada T; Yamashita G; Nagao T; Hirai H; Saigusa N; Tsukahara K
    Anticancer Res; 2022 Mar; 42(3):1547-1554. PubMed ID: 35220251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.
    Okamoto I; Tsukahara K; Sato H
    Sci Rep; 2022 Feb; 12(1):2025. PubMed ID: 35132165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and comparison of prognostic scoring systems in patients with head and neck squamous cell carcinoma treated with nivolumab.
    Takenaka Y; Takemoto N; Otsuka T; Nishio M; Tanida M; Fujii T; Hayashi K; Suzuki M; Mori M; Yamamoto Y; Uno A; Inohara H
    Jpn J Clin Oncol; 2024 Jul; 54(7):761-769. PubMed ID: 38555496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-C1GALT1 Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer.
    Lin MC; Huang MC; Lou PJ
    Laryngoscope; 2021 Jan; 131(1):E196-E202. PubMed ID: 32427353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
    Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
    In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Yamashita G; Okamoto I; Ito T; Tokashiki K; Okada T; Tsukahara K
    Anticancer Res; 2023 Aug; 43(8):3679-3683. PubMed ID: 37500154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.